Objective To observe the protective effect of Qiangxin oral liquid on experimental left ventricular hypertrophy induced by isoproterenol and ultrastructure in rats.MethodsMyocardial hypertrophy model of rats were established by injection of isoproterenol (5 mg/kg/d) for 7 days. Thirty rats were divided into the control group, model group and treatment group (treated with Qiangxin oral liquid from second day after myocardial hypertrophy model made and continued for 12 weeks). Cardiac structure and function were detected in all groups by ultrasonography on 2nd, 6th and 12th week after model made respectively. After 12 weeks, the left ventricular weight/body weight index (LVW/BW) of all animals was tested and myocardial ultrastructure was examined.ResultsCompared with the model group, the interventricular septal end systolic thickness, left ventricular posterior wall thickness, left ventricular diameter, and left ventricular mass index of the treatment group decreased significantly ( P<0.05～0.01), while the damage of myocardial ultrastructrue lightened.ConclusionQiangxin oral liquid can improve the experimental myocardial hypertrophy of rats induced by isoproterenol.

Objective To investigate the variation law of apparent diffusion coefficient (ADC) and fractional anisotropy (FA) values in patients with cerebral infarction, and to explore the relationship between the changes and the prognosis of cerebral infarct patients. Methods Sixteen patients with cerebral infarction were recruited and divided into 2 groups:good recovery and poor rehabilitation. ADC and FA values were calculated in infarct areas and control areas which were the regions with symmetrical position and the same area as infarct areas. The difference of ADC and FA values in patients at acute and earlier chronic stage between the two areas were analyzed. Results ①At acute stage, ADC values in infarct areas were lower than those in control areas (P<0.05). At early chronic stage, there was no significant difference of ADC values between infarct areas and control areas (P>0.05), moreover ADC values were higher than that at acute phase (P<0.05). ②FA values in infarct areas were lower than those in control areas at both acute and early chronic stage (P<0.05). At early chronic stage, FA values were lower than those at acute stage (P<0.05). ③There was no significant difference of ADC and FA values at both acute and early chronic stage between good recovery group compared with poor rehabilitation group (P>0.05). Conclusion There are certainly rules in changes of ADC and FA values in patients with cerebral infarction at acute and earlier chronic stage.

OBJECTIVETo study the expression of CD70 and the methylation level of CD70 promoter in immuno-related pancytopenia（IRP）patients, and explore the role of CD70 in the pathogenesis of IRP.

METHODSThirty- five IRP patients and fifteen healthy donors were enrolled in this study. Peripheral blood mononuclear cells were isolated from venous blood by density gradient centrifugation, and CD4(+) T cells were isolated by immunomagnetic beads. The mRNA level and the percentage of CD70 of CD4(+) T cells were measured by real- time quantitative polymerase chain reaction（RT- PCR）and flow cytometry respectively. Methylation- Specific PCR（MSP）was performed to determine the methylation level of CD70 promoter.

RESULTSThe percentage of CD70 expression on CD4(+) T cells of untreated IRP patients［（7.46±1.51）%］was significantly higher than that of recovered ones［（5.95±1.34）%］and normal controls［（1.83 ± 0.60）%］, and that of recovered IRP patients was significantly higher than of normal controls（P<0.05）. The relative expressions of CD70 mRNA in CD4(+) T cells were 2.314（0.200-6.084）, 1.021（0.135-3.434）, 0.353（0.008-2.258）in three groups respectively. The differences among untreated IRP patients, recovered IRP patients and normal controls were significant（P<0.05）. The CD70 promoter methylation level in CD4(+) T cells of all IRP patients was significantly lower than that of normal controls （P<0.05）. The expression of CD70 positively correlated to the ratio of CD5(+) B cells（r=0.533, P<0.01）.

CONCLUSIONThe overexpression of CD70 may lead to immunologic disarrangement of patients, which may play important role in the pathogenesis of IRP.

B-Lymphocytes ; CD27 Ligand ; CD4-Positive T-Lymphocytes ; Flow Cytometry ; Humans ; Pancytopenia ; Promoter Regions, Genetic ; RNA, Messenger ; Real-Time Polymerase Chain Reaction

Traumatic supraorbital fissure syndrome (TSOFS) is a symptom complex caused by nerve entrapment in the supraorbital fissure after skull base trauma. If the compressed cranial nerve in the supraorbital fissure is not decompressed surgically, ptosis, diplopia and eye movement disorder may exist for a long time and seriously affect the patients′ quality of life. Since its overall incidence is not high, it is not familiarized with the majority of neurosurgeons and some TSOFS may be complicated with skull base vascular injury. If the supraorbital fissure surgery is performed without treatment of vascular injury, it may cause massive hemorrhage, and disability and even life-threatening in severe cases. At present, there is no consensus or guideline on the diagnosis and treatment of TSOFS that can be referred to both domestically and internationally. To improve the understanding of TSOFS among clinical physicians and establish standardized diagnosis and treatment plans, the Skull Base Trauma Group of the Neurorepair Professional Committee of the Chinese Medical Doctor Association, Neurotrauma Group of the Neurosurgery Branch of the Chinese Medical Association, Neurotrauma Group of the Traumatology Branch of the Chinese Medical Association, and Editorial Committee of Chinese Journal of Trauma organized relevant experts to formulate Chinese expert consensus on the diagnosis and treatment of traumatic supraorbital fissure syndrome ( version 2024) based on evidence of evidence-based medicine and clinical experience of diagnosis and treatment. This consensus puts forward 12 recommendations on the diagnosis, classification, treatment, efficacy evaluation and follow-up of TSOFS, aiming to provide references for neurosurgeons from hospitals of all levels to standardize the diagnosis and treatment of TSOFS.